FibroGen, Inc. (NASDAQ:FGEN) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure |
Beginning February16, 2017, FibroGen, Inc. (the Company) intends
to conduct meetings with existing and prospective investors and
analysts in which its corporate slide presentation will be
presented. A copy of the presentation materials, including a
slide setting forth certain cautionary statements intended to
qualify the forward-looking statements therein, is attachedas
Exhibit99.1 to this Current Report on Form8-K and is incorporated
herein by reference.
The information in this Item 7.01 is being furnished, not filed,
to Regulation FD. Accordingly, the information in Item 7.01 of
this report will not be incorporated by reference into any
registration statement filed by the Company under the Securities
Act of 1933, as amended, unless specifically identified therein
as being incorporated therein by reference. The furnishing of the
information in this report is not intended to, and does not,
constitute a determination or admission by the Company that the
information in this report is material or complete, or that
investors should consider this information before making an
investment decision with respect to any security of the Company.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit No. |
Description |
|
| 99.1 | FibroGen,Inc. Presentation Materials dated February16, 2017 |
About FibroGen, Inc. (NASDAQ:FGEN)
FibroGen, Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body’s natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies. FibroGen, Inc. (NASDAQ:FGEN) Recent Trading Information
FibroGen, Inc. (NASDAQ:FGEN) closed its last trading session down -0.15 at 24.25 with 283,553 shares trading hands.
